2. Results
A total of 885 patients with UC were included in the KARMS database, and 654 patients (75.1%) with microbiologically proven E. coli were eligible for the present study (Table 1). The other causative bacterial pathogens for UC were Klebsiella pneumoniae (6.2%, 54), followed by Enterococcus spp. (4.1%, 36), Streptococcus spp. (3.8%, 33), and Proteus mirabilis (3.0%, 26).
The mean (standard deviation) patient age was 55.87 (18.31) years. The numbers of patients in primary, secondary, and tertiary medical centers were 271 (30.7%), 418 (48.0%) and 195 (34.0%), respectively. Regarding hospital region, most patients were in Gyeonggi Province (n = 264, 40.4%), followed by Seoul (189, 28.9%), Jeolla (99, 15.1%), Gyeongsang (78, 11.9%), and Chungcheong (24, 3.7%). The numbers of patients with community-acquired UTIs, postmenopausal status, and recurrent cystitis were 648 (99.2%), 260 (40.6%), and 78 (11.9%), respectively. ESBL positivity was 14.4% (89/616).
2.2. Antimicrobial Susceptibility of E. coli
Overall, 50.9% (324/636) were susceptible to ciprofloxacin, 82.4% (521/632) to cefotaxime, 96.8% (61/63) to fosfomycin, 98.9% (187/189) to nitrofurantoin, 99.7% (627/629) to amikacin, 82.7% (497/601) to amoxicillin/clavulanate, 61.0% (108/177) to levofloxacin, 68.1% (399/586) to trimethoprim/sulfamethoxazole, 97.5% (624/640) to piperacillin/tazobactam, and 100% (718/718) to ertapenem (Table 2). Thus, the resistance rates for E. coli to ciprofloxacin and cefotaxime in patients with UC were 49.1% and 17.6%, respectively.
2.3. Assessment of E. coli AMR by Clinical Factors
The rates of ESBL positivity, fluoroquinolone resistance, and third-generation cephalosporin resistance were compared according to clinical factors such as hospital type, hospital region, menopausal status, and recurrence. There were no significant differences observed according to hospital region. ESBL positivity was significantly higher in tertiary hospitals (primary 7.8%, secondary 13.8%, tertiary 24.6%; p < 0.001) and patients with recurrent cystitis (non-recurrence 12.4%, recurrence 27.6%; p < 0.001). Fluoroquinolone resistance was significantly higher in tertiary hospitals (primary 31.7%, secondary 47.1%, tertiary 57.8%; p < 0.001), postmenopausal women (premenopausal 30.6%, postmenopausal 54.2%; p < 0.001), and patients with recurrent cystitis (non-recurrence 41.0%, recurrence 70.3%; p < 0.001). In addition, resistance to third-generation cephalosporins was significantly higher in tertiary hospitals (primary 11.3%, secondary 17.1%, tertiary 23.0%; p = 0.033) and postmenopausal women (premenopausal 12.6%, postmenopausal 19.6%; p = 0.004) (Figure 1).
2.4. Assessment of Clinical Factors Associated with Fluoroquinolone Resistance and ESBL Positivity
Tertiary hospitals (95% confidence interval [CI]: 1.00–2.93, odds ratio [OR] 1.71; p = 0.049), postmenopausal status (95% CI: 1.44–3.17, OR 2.13; p < 0.001), and recurrent cystitis (95% CI: 1.40–4.66, OR 2.56; p = 0.002) were associated with increased fluoroquinolone resistance (Table 3). In addition, tertiary hospitals (95% CI: 1.59–6.26, OR 3.15; p = 0.001) and recurrent cystitis (95% CI: 1.01–3.41, OR 1.86; p = 0.045) were associated with increased ESBL positivity (Table 4).
CC BY 4.0. "Antimicrobial Resistance of Escherichia coli for Uncomplicated Cystitis: Korean Antimicrobial Resistance Monitoring System" by Yu SH, Jung SI, Lee SJ et al., Antibiotics (Basel, Switzerland) (2024). https://doi.org/10.3390/antibiotics13111075. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Peer-reviewed and open access; full text from PubMed Central (PMC11591001). Headings and layout adapted for reading; figures and tables are in the original.